BCG immunotherapy for recurrent malignant melanoma - A study of delayed hypersensitivity to recall antigens and relationship to prognosis

Shelley L. Rasmussen, Jordan U. Gutterman, Evan M. Hersh, Sydney Boston, M. Marshall, Barry W. Brown

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

A study was made of immunologic parameters obtained from patients with stage IIIB malignant melanoma who were treated with BCG. Patients with the longest disease-free interval and survival times were those who had small initial skin test reactions and developed larger reactions during the course of BCG treatment. Of these patients, those with less than five involved nodes had the longest disease-free interval and survival times. Patients who had increases in skin test reactivity generally showed these increases by the first visit after initiation of BCG therapy.

Original languageEnglish (US)
Pages (from-to)17-26
Number of pages10
JournalCancer Immunology Immunotherapy
Volume10
Issue number1
DOIs
StatePublished - Mar 1980

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'BCG immunotherapy for recurrent malignant melanoma - A study of delayed hypersensitivity to recall antigens and relationship to prognosis'. Together they form a unique fingerprint.

  • Cite this